(E)-3-(4-((2-methoxyethoxy)methoxy)phenyl)acrylic acid | 96400-72-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(4-((2-methoxyethoxy)methoxy)phenyl)acrylic acid
• 英文别名: (E)-3-{4-[(2-methoxyethoxy)methoxy]phenyl}acrylic acid；p-methoxyethoxymethyloxy-cinnamic acid；4-[(2-methoxyethoxy)methoxy]cinnamic acid；3-[4-(2-Methoxy-ethoxymethoxy)-phenyl]-acrylic acid；(E)-3-[4-(2-methoxyethoxymethoxy)phenyl]prop-2-enoic acid
• CAS: 96400-72-5
• 化学式: C₁₃H₁₆O₅
• 分子量: 252.267
• InChiKey: FMVLEXYKBJAJMW-QPJJXVBHSA-N

物化性质

• 沸点：
  422.9±35.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-((2-methoxyethoxy)methoxy)phenyl)acrylic acid 在 N,N'-二环己基碳二亚胺 作用下， 反应 15.0h， 以87.8%的产率得到(E)-3-(4-((2-methoxyethoxy)methoxy)phenyl)acrylic anhydride
  参考文献：
  名称：

  Takano, Seiichi; Shishido, Kozo, Chemical and pharmaceutical bulletin, 1984, vol. 32, # 10, p. 3892 - 3899

  摘要：

  DOI：
• 作为产物：
  描述：

  4-香豆酸 在 硫酸 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 38.0h， 生成 (E)-3-(4-((2-methoxyethoxy)methoxy)phenyl)acrylic acid
  参考文献：
  名称：

  Discovery of a series of selective and cell permeable beta-secretase (BACE1) inhibitors by fragment linking with the assistance of STD-NMR

  摘要：

  Two beta-secreatase (BACE1) inhibitors from natural products (cinnamic acid and flavone) were linked to furnish potent, cell permeable BACE1 inhibitors with noncompetitive mode of inhibition, with the assistance of saturated transfer difference (STD)-NMR technique. Some of these conjugates also exhibited selective BACE1 inhibition over other aspartyl proteases such as BACE-2 and renin, as well as poor cytotoxicity. Taken together, conjugates 4 represent a new series of BACE inhibitors warrants further investigation for their potential in Alzheimier's disease therapy.

  DOI：

  10.1016/j.bioorg.2019.103253

文献信息

• [EN] (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS<br/>[FR] COMPOSÉS (HÉTÉRO)ARYLE CYCLOPROPYLAMINES EN TANT QU'INHIBITEURS DE LSD1
  申请人：ORYZON GENOMICS SA

  公开号：WO2013057320A1

  公开（公告）日：2013-04-25

  The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

  本发明涉及（杂）芳基环丙胺化合物，特别是如本文所述和定义的公式I的化合物，以及它们在治疗中的用途，例如，在治疗或预防癌症、神经疾病或状况、或病毒感染中的用途。
• Cinnamamide derivatives and drug compositions containing the same
  申请人：Tsumura & Co.

  公开号：US06413995B1

  公开（公告）日：2002-07-02

  The invention relates to cinnamamide derivatives having the following formula wherein R1 represents a hydroxyl group, a C1-6-alkoxy group, an arylalkoxy group or a substituted or unsubstituted amino group; R2 and R3 are same or different, each of which represents a hydrogen atom, a halogen atom or a C1-4-alkyl group; R4 represents a hydrogen atom or a C1-6-alkyl group; R5 represents a hydrogen atom, a C1-6-alkyl group or an aryl group; R6 represents a hydrogen atom, a C1-6-alkyl group, a cyano group or a C1-6-alkoxy-carbonyl group; W represents an oxygen atom, a sulfur atom, an imino group, a methylene group, a hydroxymethylene group or a carbonyl group; X and Y are same or different, each of which represents an oxygen atom or a sulfur atom; m represents an integer of 0 to 2; n represents an integer of 1 to 3; and when m is 0, a group: —C(R2)(R3)—W— may represent a vinylene group; or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the above compound, in particular, an immunomodulatory agent and a prophylactic or therapeutic agent for nephrotic syndrome, circulatory disorders or respiratory diseases.

  该发明涉及具有以下结构的肉桂酰胺衍生物，其中R1代表一个羟基、一个C1-6-烷氧基、一个芳基烷氧基或一个取代或未取代的氨基；R2和R3相同或不同，分别代表一个氢原子、一个卤原子或一个C1-4烷基基团；R4代表一个氢原子或一个C1-6烷基基团；R5代表一个氢原子、一个C1-6烷基基团或一个芳基；R6代表一个氢原子、一个C1-6烷基基团、一个氰基或一个C1-6烷氧羰基；W代表一个氧原子、一个硫原子、一个亚胺基、一个亚甲基基团、一个羟基亚甲基基团或一个羰基基团；X和Y相同或不同，分别代表一个氧原子或一个硫原子；m代表0到2之间的整数；n代表1到3之间的整数；当m为0时，一个基团：—C(R2)(R3)—W—可以表示一个乙烯基团；或其药学上可接受的盐；以及含有上述化合物的药物组合物，特别是一种免疫调节剂和一种肾病综合征、循环障碍或呼吸道疾病的预防或治疗剂。
• (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
  申请人：ORYZON GENOMICS, S.A.

  公开号：US20150025054A1

  公开（公告）日：2015-01-22

  The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

  本发明涉及（杂）芳基环丙胺化合物，特别是本文所述并定义的I式化合物，以及它们在治疗中的应用，包括例如用于治疗或预防癌症、神经疾病或病况，或病毒感染。
• CINNAMAMIDE DERIVATIVES AND DRUG COMPOSITIONS CONTAINING THE SAME
  申请人：TSUMURA & CO.

  公开号：EP1142875A1

  公开（公告）日：2001-10-10

  The invention relates to cinnamamide derivatives having the following formula (I): wherein R1 represents a hydroxyl group, a C1-6-alkoxy group, an arylalkoxy group or a substituted or unsubstituted amino group; R2 and R3 are same or different, each of which represents a hydrogen atom, a halogen atom or a C1-4-alkyl group; R4 represents a hydrogen atom or a C1-6-alkyl group; R5 represents a hydrogen atom, a C1-6-alkyl group or an aryl group; R6 represents a hydrogen atom, a C1-6-alkyl group, a cyano group or a C1-6-alkoxy-carbonyl group; W represents an oxygen atom, a sulfur atom, an imino group, a methylene group, a hydroxymethylene group or a carbonyl group; X and Y are same or different, each of which represents an oxygen atom or a sulfur atom; m represents an integer of 0 to 2; n represents an integer of 1 to 3; and    when m is 0, a group: -C(R2)(R3)-W- may represent a vinylene group; or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the above compound, in particular, an immunomodulatory agent and a prophylactic or therapeutic agent for nephrotic syndrome, circulatory disorders or respiratory diseases.

  本发明涉及具有下式(I)的肉桂酰胺衍生物： 其中 R1 代表羟基、C1-6-烷氧基、芳基烷氧基或取代或未取代的氨基； R2 和 R3 相同或不同，各自代表氢原子、卤素原子或 C1-4- 烷基； R4 代表氢原子或 C1-6- 烷基 R5 代表氢原子、C1-6-烷基或芳基； R6 代表氢原子、C1-6-烷基、氰基或 C1-6- 烷氧基羰基； W 代表氧原子、硫原子、亚氨基、亚甲基、羟甲基或羰基； X 和 Y 相同或不同，各自代表氧原子或硫原子； m 代表 0 至 2 的整数； n 代表 1 至 3 的整数；以及 当 m 为 0 时，基团：-C(R2)(R3)-W- 可代表乙烯基；或其药学上可接受的盐；以及含有上述化合物的药物组合物，特别是免疫调节剂和肾病综合征、循环系统疾病或呼吸系统疾病的预防或治疗剂。
• (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
  申请人：Oryzon Genomics, S.A.

  公开号：US10329256B2

  公开（公告）日：2019-06-25

  The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

  本发明涉及(杂)芳基环丙胺化合物，尤其包括本文所描述和定义的式 I 化合物，以及它们在治疗中的用途，包括治疗或预防癌症、神经系统疾病或病症或病毒感染等。